Cabaletta Bio, Inc. Profile Avatar - Palmy Investing

Cabaletta Bio, Inc.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor…

Biotechnology
US, Philadelphia [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of CABA's Analysis
CIK: 1759138 CUSIP: 12674W109 ISIN: US12674W1099 LEI: - UEI: -
Secondary Listings
CABA has no secondary listings inside our databases.